Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
100%(4 trials)

Phase Distribution

Ph phase_2
2
40%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(4)

Detailed Status

Completed4
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 33 (60.0%)

Trials by Status

active_not_recruiting120%
completed480%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_3

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102
completedphase_2

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03398148
completedphase_3

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03105128
completedphase_3

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

NCT03104413
completedphase_2

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

NCT02031276

Clinical Trials (5)

Showing 5 of 5 trials
NCT03105102Phase 3

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Active Not Recruiting
NCT03398148Phase 2

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Completed
NCT03105128Phase 3

A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Completed
NCT03104413Phase 3

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Completed
NCT02031276Phase 2

Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5